Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab for Hidradenitis Suppurativa
NCT06374212Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Jun 2024
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anifrolumab in hidradenitis suppurativa (HS), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Hidradenitis Suppurativa Clinical Response 50 at 12 weeks. Started Jun 2024; status: completed.
02
Drugs
anifrolumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06374212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06374212.